Dysphagia (grade >= 3, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in dysphagia (grade >= 3, 0-4 scale) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Disease-free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in disease-free survival compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in quality of life compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes salivary flow rate (mg/5 min, unstimulated) compared with no treatment/placebo (very low certainty).
2 findings from 1 review
Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in progression-free survival compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Dysgeusia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine led to lower dysgeusia (grade >= 2, 0-4 scale) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Cost (mean per-patient supportive care costs) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue reported narratively or only for the amifostine group; insufficient evidence of a difference
Studies not reported
GRADE not reported
Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to lower xerostomia (grade >= 2, 0-4 scale) compared with no treatment/placebo (low certainty).
3 findings from 1 review
RR 0.35 [0.19, 0.67]
3 studies · 119 participants
Low
RR 0.70 [0.40, 1.23]
7 studies · 682 participants
Low
RR 0.66 [0.48, 0.92]
5 studies · 687 participants
Low
Allergic adverse events · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to higher allergic response (adverse effect) compared with no treatment/placebo (low certainty).
1 finding from 1 review
Vomiting · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to higher vomiting (adverse effect) compared with no treatment/placebo (low certainty).
1 finding from 1 review
Asthenia · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in asthenia (adverse effect) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes overall survival compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Locoregional control · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in locoregional tumour control compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Nausea · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to higher nausea (adverse effect) compared with no treatment/placebo (low certainty).
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine led to higher salivary flow rate (incidence of > 0.1 g saliva/5 min, unstimulated) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Adverse events: hypotension · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to higher hypotension (adverse effect) compared with no treatment/placebo (low certainty).
1 finding from 1 review
Quality of life (Patient Benefit Questionnaire, 10-point scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes quality of life (Patient Benefit Questionnaire, 10-point scale) compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Locoregional control · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine (intravenous) showed no clear difference in locoregional tumour control compared with amifostine (subcutaneous); GRADE not reported.
1 finding from 1 review
HR 1.34 [0.76, 2.36]
1 study
GRADE not reported